ReBio Pharma at ISOO 2026
Turku, Finland and Geneva, Switzerland, 24 March 2026 – ReBio Pharma participated as a proud sponsor of the International Society of Ocular Cancer (ISOO) 2026 in Rio de Janeiro from 17–21 March 2026. The company presented data on its lead candidate, RBP-01, a novel therapy for uveal melanoma. The data demonstrated continuous and potent exposure to PKC inhibition in tumor-relevant ocular tissues with favourable tolerability, supporting its use as a novel targeted therapy for primary uveal melanoma. The presentation was co-authored by Roi Raz (CEO), Harri Jukarainen (co-CTO) and Chiara Conti (Chief Scientific Advisor).
Presentation Details:
- Title: RBP-01: A Novel Localized Targeted Therapy Designed to Achieve Potent PKC Inhibition for the Treatment of Primary Uveal Melanoma with GNAQ/11 Activating Mutations
- Presenter: Mandeep Sagoo, Scientific Advisor
- Location: Gávea AB, Main Auditorium
- Date: 19 March 2026
- Abstract: View Abstract
About ReBio Pharma:
ReBio Pharma is a European biotechnology company developing novel, targeted, vision-preserving therapies for ocular oncology. RBP-01, built on our SiSu® therapeutic amplifier technology, is designed to enhance PKC inhibition directly to the tumor site for the treatment of primary uveal melanoma. ReBio is advancing RBP-01 toward clinical trials in 2026 while pursuing additional programs targeting uveal melanoma and retinoblastoma, expanding therapeutic possibilities with programmable drug exposure.
